Herantis Pharma Oyj
Herantis Pharma Oyj
Your view on HRPMF
Overview
What the company does, where it operates, and who runs it.
About Herantis Pharma Oyj
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Antti Vuolanto D.Sc. (Tech)
- Headquarters
- Bertel Jungin Aukio 1, Espoo, FI
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Antti Vuolanto D.Sc. (Tech)
- Headquarters
- Bertel Jungin Aukio 1, Espoo, FI
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.